Top Markets
Coin of the day
Becton, Dickinson and Company Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Classificação em ações #492
Operating globally, Becton, Dickinson and Company (BD) is a prominent... Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Preço da ação
$183.43
Valor de mercado
$50.54B
Variação (1 dia)
2.13%
Variação (1 ano)
29.20%
País
US
Negociar Becton, Dickinson and Company (BDX)

Categoria

Rácio P/E de Becton, Dickinson and Company (BDX)
Rácio P/E em September 2026 TTM: 55.09
De acordo com os últimos relatórios financeiros e o preço das ações da Becton, Dickinson and Company, o rácio P/E atual (TTM) é 55.09. No final de 2024, a empresa tinha um P/E de 40.97.
Histórico do rácio P/E da Becton, Dickinson and Company de 2000 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
2026 (TTM) 55.09 72.33%
2025 31.97 -21.98%
2024 40.97 -17.84%
2023 49.87 39.71%
2022 35.70 7.72%
2021 33.14 -54.23%
2020 72.41 34.11%
2019 53.99 -74.78%
2018 214.12 463.11%
2017 38.02 -0.43%
2016 38.19 1.32%
2015 37.69 108.24%
2014 18.10 22.98%
2013 14.72 8.89%
2012 13.52 8.66%
2011 12.44 -3.18%
2010 12.85 -3.24%
2009 13.28 -21.73%
2008 16.96 -23.68%
2007 22.23 -1.92%
2006 22.66 27.31%
2005 17.80 -34.36%
2004 27.12 65.54%
2003 16.38 10.04%
2002 14.89 -35.06%
2001 22.93 38.04%
2000 16.61 0.00%
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
42.71 -22.49%
US
27.35 -50.35%
FR
- -
JP
- -
CH
- -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.